Half-Year 2022 Financial and Clinical Trials Update
Tecentriq
Anti-PD-L1 cancer immunotherapy - lung cancer
Indication
Adjuvant NSCLC
Neoadjuvant NSCLC
Phase/study
# of patients
Design
Phase III
IMpower010
N=1,280
Following adjuvant cisplatin-based chemotherapy
ARM A: Tecentriq
ARM B: Best supportive care
Phase III
IMpower030
N=450
ARM A: Tecentriq plus platinum-based chemotherapy
ARM B: Platinum-based chemotherapy
Primary endpoint
Status
Disease-free survival
Trial amended from PD-L1+ selected patients to all-comers
FPI for all-comer population Q4 2016
Recruitment completed Q3 2018
Study met primary endpoint Q1 2021
Data presented at ASCO, WCLC and ESMO 2021
Filed in US (priority review) and EU Q2 2021
▪ Approved in US Q4 2021 and EU Q2 2022
CT Identifier
NCT02486718
Event-free survival
☐
FPI Q2 2018
Recruitment completed Q3 2021
NCT03456063
NSCLC-non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1; ASCO-American Society of Clinical Oncology; ESMO==European Society for Medical Oncology; WCLC-World Conference on Lung Cancer
87
Roche
OncologyView entire presentation